Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VXRT

Vaxart Inc

Sep 27 • 04:00PM ET

0.8211

Dollar change +0.0131
Percentage change 1.62	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF ONEQ QQQS RFLR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.46	Insider Own	0.87%	Shs Outstand	227.44M	Perf Week	-1.59%
Market Cap	186.75M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	1.02%	Shs Float	225.47M	Perf Month	-3.40%
Income	-75.66M	PEG	-	EPS next Q	-0.10	Inst Own	24.61%	Short Float	5.61%	Perf Quarter	23.05%
Sales	13.93M	P/S	13.41	EPS this Y	16.96%	Inst Trans	7.53%	Short Ratio	5.82	Perf Half Y	-36.84%
Book/sh	0.35	P/B	2.33	EPS next Y	12.68%	ROA	-64.01%	Short Interest	12.64M	Perf Year	13.88%
Cash/sh	0.28	P/C	2.98	EPS next 5Y	-	ROE	-91.66%	52W Range	0.52 - 1.54	Perf YTD	43.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.81%	ROI	-77.53%	52W High	-46.68%	Beta	0.67
Dividend TTM	-	Quick Ratio	4.54	Sales past 5Y	1341.69%	Gross Margin	66.97%	52W Low	57.90%	ATR (14)	0.07
Dividend Ex-Date	Nov 09, 2012	Current Ratio	4.54	EPS Y/Y TTM	39.20%	Oper. Margin	-538.83%	RSI (14)	46.54	Volatility	7.40% 7.49%
Employees	125	Debt/Eq	0.29	Sales Y/Y TTM	577.76%	Profit Margin	-543.21%	Recom	1.00	Target Price	4.83
Option/Short	Yes / Yes	LT Debt/Eq	0.22	EPS Q/Q	44.83%	Payout	-	Rel Volume	0.55	Prev Close	0.81
Sales Surprise	6301.00%	EPS Surprise	40.00%	Sales Q/Q	371.35%	Earnings	Aug 08 AMC	Avg Volume	2.17M	Price	0.82
SMA20	-6.70%	SMA50	4.64%	SMA200	-4.60%	Trades		Volume	1,205,572	Change	1.62%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-24	Initiated	Oppenheimer	Outperform	$4
Dec-29-21	Resumed	Jefferies	Buy	$13 → $12
Nov-02-21	Initiated	Cantor Fitzgerald	Overweight	$15
Jun-29-21	Downgrade	B. Riley Securities	Buy → Neutral	$13 → $9
Jun-24-21	Initiated	Jefferies	Buy	$13
Jun-11-21	Initiated	Piper Sandler	Overweight	$18
Aug-12-20	Reiterated	H.C. Wainwright	Buy	$7 → $17
Jul-13-20	Initiated	B. Riley FBR	Buy	$22

Aug-30-24 08:00AM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-24 08:00AM	Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia (GlobeNewswire)
Aug-15-24 01:57PM	Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside (Benzinga) +25.66%
Aug-09-24 11:48AM	Q2 2024 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents) -7.95%
Aug-08-24 09:59PM	VXRT Stock Earnings: Vaxart Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) +5.74%
05:30PM	Loading…
05:30PM	VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-02-24 08:00AM	Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8 (GlobeNewswire) -5.95%
Jun-17-24 04:05PM	Vaxart Provides Business Update (GlobeNewswire) -8.25% +30.16%
Jun-14-24 10:06AM	Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering (Benzinga) -23.67%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-13-24 07:07PM	Vaxart Announces $40 Million Underwritten Offering of Common Stock (GlobeNewswire)
04:15PM	Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire)
May-23-24 04:01PM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.46%
May-14-24 01:07PM	Q1 2024 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents) +5.45%
08:20AM	Loading…
08:20AM	Vaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:07AM	Vaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ... (GuruFocus.com)
May-13-24 08:56PM	VXRT Stock Earnings: Vaxart Meets EPS, Beats Revenue for Q1 2024 (InvestorPlace) +16.31%
04:01PM	Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 08:00AM	Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13 (GlobeNewswire)
Apr-30-24 08:00AM	Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers (GlobeNewswire)
Apr-09-24 04:30PM	Election Year Encore: Can 2020s Top 7 Stock Winners Repeat Their Performance in 2024? (InvestorPlace)
Mar-27-24 08:00AM	Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 (GlobeNewswire) +5.74%
Mar-20-24 08:00AM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.90%
Mar-15-24 01:45PM	Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:33AM	Q4 2023 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 08:55PM	VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:35PM	Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:01PM	Vaxart Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-07-24 08:00AM	Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 (GlobeNewswire) -7.50%
08:00AM	Loading…
Mar-06-24 08:00AM	Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director (GlobeNewswire)
Feb-26-24 12:00PM	VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-20-24 09:55AM	VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Feb-05-24 08:00AM	Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge (GlobeNewswire)
Jan-19-24 08:30AM	Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire) -6.59%
Jan-16-24 09:25AM	Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management (GlobeNewswire) +29.41%
09:22AM	Vaxart, Inc. Announces Management Change (GlobeNewswire)
Dec-21-23 08:00AM	Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers (GlobeNewswire)
Nov-03-23 11:47AM	Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.09%
Nov-02-23 06:39PM	Vaxart Inc (VXRT) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:01PM	Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
08:00AM	Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers (GlobeNewswire)
Oct-26-23 08:00AM	Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2 (GlobeNewswire)
Oct-11-23 08:00AM	Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19 (GlobeNewswire)
Sep-21-23 08:00AM	Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-12-23 12:48PM	3 Biotech Blockbusters to Turn $5,000 Into $50,000 (InvestorPlace)
Sep-06-23 04:05PM	Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate (GlobeNewswire) -8.00%
Aug-15-23 01:46PM	Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' Now (Zacks)
Aug-05-23 06:39AM	Vaxart, Inc. (NASDAQ:VXRT) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:15PM	VAXART, INC. (VXRT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-27-23 08:00AM	Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3 (GlobeNewswire)
Jul-06-23 08:00AM	Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate (GlobeNewswire)
Jun-26-23 04:45PM	Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement (GlobeNewswire) -15.28%
Jun-21-23 04:30PM	Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET (GlobeNewswire) +5.31%
Jun-07-23 09:16AM	Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock (GlobeNewswire) -27.41%
Jun-06-23 04:01PM	Vaxart, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:00AM	Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate (GlobeNewswire)
May-31-23 08:00AM	Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET (GlobeNewswire)
07:47AM	Here's Why We're A Bit Worried About Vaxart's (NASDAQ:VXRT) Cash Burn Situation (Simply Wall St.)
May-04-23 04:01PM	Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-28-23 08:00AM	Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4 (GlobeNewswire) +6.01%
Apr-24-23 05:30AM	These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge (Motley Fool)
Mar-29-23 08:00AM	Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6 (GlobeNewswire) +6.70%
Mar-18-23 02:56AM	Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 08:00AM	Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus (GlobeNewswire)
Mar-15-23 04:01PM	Vaxart Provides Business Update and Full Year 2022 Financial Results (GlobeNewswire)
Mar-08-23 04:05PM	Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15 (GlobeNewswire) -8.66%
Feb-14-23 08:00AM	Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate (GlobeNewswire)
Jan-18-23 09:00AM	Covid Isnt Going Away. New Drugs Are Coming. (Barrons.com)
Jan-09-23 08:27AM	Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Dec-19-22 08:00AM	Vaxart Names Phillip Lee as Chief Financial Officer (GlobeNewswire) -14.51%
Dec-01-22 08:00AM	Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers (GlobeNewswire)
Nov-22-22 08:30AM	Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29 (GlobeNewswire)
Nov-11-22 05:47AM	Vaxart Third Quarter 2022 Earnings: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021) (Simply Wall St.) +7.10%
Nov-08-22 05:45PM	VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -9.35%
04:01PM	Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-01-22 10:01AM	VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-22 05:06AM	3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall Street (Motley Fool) +5.59%
Oct-20-22 08:30AM	Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8 (GlobeNewswire)
Oct-10-22 08:00AM	Vaxart to Present at World Vaccine Congress Europe 2022 on October 13 (GlobeNewswire) -5.70%
Oct-04-22 06:20AM	2 Struggling Stocks to Avoid Right Now (Motley Fool)
Sep-07-22 08:30AM	Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 06:30AM	Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate (GlobeNewswire)
Aug-31-22 04:30PM	Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial (GlobeNewswire)
08:30AM	Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer (GlobeNewswire)
Aug-25-22 04:05PM	Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors (GlobeNewswire) -5.35% -8.93%
Aug-08-22 05:35PM	VAXART, INC. (VXRT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
08:00AM	Vaxart Appoints W. Mark Watson to its Board of Directors (GlobeNewswire)
Aug-05-22 08:00AM	Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4 (GlobeNewswire) +5.12%
Aug-03-22 07:55AM	Could This Unknown Stock Beat Moderna in 2023? (Motley Fool)
Jul-29-22 10:56AM	Tablet Covid vaccine hopeful settles suit claiming it overhyped its prospects for success (American City Business Journals)
Jul-28-22 04:05PM	Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8 (GlobeNewswire)
Jul-27-22 08:00AM	Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET (GlobeNewswire)
Jul-20-22 08:30AM	Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive (GlobeNewswire) +7.58%
Jul-14-22 08:00AM	Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022 (GlobeNewswire)
Jul-01-22 09:00AM	Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET (GlobeNewswire) +7.14%
Jun-30-22 08:00AM	Vaxart Announces Agreement with hVIVO to Develop Worlds First Human Omicron Challenge Model (GlobeNewswire)
Jun-29-22 06:00AM	3 Revolutionary Stocks I'd Buy Right Now Without Hesitation (Motley Fool)

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Watson W. Mark	Director	Jun 18 '24	Buy	0.68	20,000	13,578	78,125	Jun 20 06:10 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VXRT

Vaxart Inc

Upgrade your FINVIZ experience